New eczema cream studied in kids and adults – could reduce steroid use?

NCT ID NCT07014007

Recruiting now Symptom relief Sponsor: Pierre Fabre Dermo Cosmetique Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a cream called RV4421B-EV0407, a medical device already sold in some countries, for mild to moderate atopic dermatitis (eczema). It includes 105 participants from 3 months old to adults, with diverse skin types. The cream is used alone or with steroid creams for up to 12 weeks. Researchers are checking how well the skin tolerates it and if it helps control eczema.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RV4421B-EV0407 cream (medical device)
What this could lead to: If successful, this could provide a well-tolerated, steroid-sparing option for managing eczema symptoms across diverse skin types and ages.
What could go wrong: This is an early-phase, open-label study with no placebo group, so results may be biased. The cream is already marketed, but long-term efficacy and safety in diverse populations are still being confirmed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema dermatitis Eczema Erythema Paresthesia Pruritus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

Insight Research Ltd
RECRUITING

Quatre Bornes, Mauritius, 742CU001, Mauritius

More trials for these conditions

Other studies related to the condition(s) this trial covers.